Daniel G. Haller
Abramson Cancer Center
University of Pennsylvania
Philadelphia
PA 19104
USA
Name/email consistency: high
- Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. Haller, D.G., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., Hill, M., Gilberg, F., Rittweger, K., Schmoll, H.J. J. Clin. Oncol. (2011)
- Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. Haller, D.G., Rothenberg, M.L., Wong, A.O., Koralewski, P.M., Miller, W.H., Bodoky, G., Habboubi, N., Garay, C., Olivatto, L.O. J. Clin. Oncol. (2008)
- Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. Haller, D.G., Catalano, P.J., Macdonald, J.S., O'Rourke, M.A., Frontiera, M.S., Jackson, D.V., Mayer, R.J. J. Clin. Oncol. (2005)
- Chemotherapy for advanced pancreatic cancer. Haller, D.G. Int. J. Radiat. Oncol. Biol. Phys. (2003)